title: Neuroleptic malignant syndrome and catatonia  in a patient with dementia.
authors.forename: Dhiren
authors.initials: D
authors.lastname: Singh
authors.forename: Rosaria
authors.initials: R
authors.lastname: Forlano
authors.forename: Robert
authors.initials: R
authors.lastname: Athey
mesh_terms: D000368:Aged; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects; D002389:Catatonia / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage; D003072:Cognition Disorders / Q000188:drug therapy / Q000523:psychology; D003402:Creatine Kinase / Q000097:blood / Q000187:drug effects; D003704:Dementia / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D018450:Disease Progression; D000077265:Donepezil; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage; D008140:Lorazepam / Q000008:administration & dosage; D009127:Muscle Rigidity / Q000139:chemically induced; D009459:Neuroleptic Malignant Syndrome / Q000150:complications / Q000175:diagnosis* / Q000523:psychology; D000077152:Olanzapine; D010880:Piperidines / Q000008:administration & dosage; D012008:Recurrence; D018967:Risperidone / Q000008:administration & dosage
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D007189:Indans; D010880:Piperidines; D001569:Benzodiazepines; D000077265:Donepezil; D003402:Creatine Kinase; D018967:Risperidone; D000077152:Olanzapine; D008140:Lorazepam; D002746:Chlorpromazine